Analyst consensus rating
Cogent Biosciences Analyst Rating: Strong Buy
COGT is rated Strong Buy by 11 analysts with a $55.82 target. As of 2026-08-31.
Direct answer
Cogent Biosciences's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $55.82.
Forecast evidence checked August 31, 2026.
Get free Cogent Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $34.67
- Average price target
- $55.82
- High price target
- $62.00
- Low price target
- $45.00
- Low target gap
- +29.8%
- Target upside
- +61%
- High target gap
- +78.8%
- Target range width
- 49%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cogent Biosciences?
Cogent Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $55.82.
How far are Cogent Biosciences's low and high targets from the recorded price?
The low target implies +29.8%, while the high target implies +78.8%.
How many analysts are included in Cogent Biosciences's consensus?
The verified consensus includes 11 analysts.
How is Cogent Biosciences's target upside or downside calculated?
The average target of $55.82 is divided by the recorded price of $34.67, then one is subtracted to produce +61%. This does not guarantee a future return.
When was Cogent Biosciences's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.